NPNaveen L. Pereira

Naveen L. Pereira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naveen L. Pereira has a total of 738 co-authors. Here are the top co-authors by number of shared publications:

  • Sudhir S. Kushwaha

    Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

    12 shared publications
  • Brooks S. Edwards

    From Department of Cardiovascular Diseases (K.L.W., S.S.K., B.S.E., N.L.P.), Department of Surgery (T.T., R.C.D.), Department of Health Sciences Research (B.H.S., W.K.K.), Department of Laboratory Medicine and Pathology (M.J.G.), and Department of Molecular Pharmacology and Experimental Therapeutics (N.L.P.), Mayo Clinic, Rochester, MN

    8 shared publications
  • Duan Liu

    Mayo Clinic

    8 shared publications
  • Kent Bailey

    Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA

    8 shared publications
  • Margaret M. Redfield

    Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN

    8 shared publications
  • Michael E. Farkouh

    Academic Affairs, Cedars-Sinai Health System, Los Angeles, California, USA

    8 shared publications

Latest Publications

  • Incidence of Atrial and Ventricular Arrhythmias in Patients With Titin Truncating Variants Across the Ventricular Morphofunctional Phenotypic Spectrum

    by Roxanne Coderre, William H. Swain, Matteo Castrichini, Ramin Garmany, Konstantinos C. Siontis, J. Martijn Bos, Naveen L. Pereira, Michael J. Ackerman, John R. Giudicessi


  • Open Access

    Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI

    by Caroline W. Grant, Brenden S. Ingraham, Ryan J. Lennon, Anvi Raina, Shulan Tian, Gurukripa Kowlgi, Larisa H. Cavallari, Craig R. Lee, Amber Beitelshees, Dominick J. Angiolillo, et al.

    Ischemic events after contemporary percutaneous coronary intervention (PCI) are uncommon but carry high morbidity/mortality. Identifying patients at highest risk is critical to guide dual antiplatelet therapy (DAPT) intensity while minimizing bleeding. Current machine learning (ML) model‐developed risk scores do not incorporate pharmacogenetic data. To develop and externally validate ML models that integrate clinical, demographic, and CYP2C19 genetic information to predict 1‐year ischemic outcomes post‐PCI to refine clinical decision making. We analyzed 8317 patients from TAILOR‐PCI trial ( n = 4572) and the Precision PCI registry ( n = 3745). The outcome was a composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis at 1 year. Boruta feature selection identified 11 predictors. Multiple ML algorithms were trained in TAILOR‐PCI and validated in Precision PCI using cross‐validation and synthetic minority oversampling (SMOTE). Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The best external performance was achieved with a support vector machine (SVM, polynomial kernel) (AUC 0.667; sensitivity 0.871; specificity 0.282), while XGBoost provided a more balanced profile (AUC 0.619; sensitivity 0.442; specificity 0.688). Variable importance for the SVM polynomial model demonstrated that all 11 included Boruta feature selected predictors had relatively high importance (> 75). ML models trained on large clinical trial and real‐world registry datasets can help identify the small subset of patients at high ischemic risk after PCI. This distinction is of relevance because ischemic events are rare, and most patients may safely de‐escalate DAPT to reduce bleeding risk while maintaining ischemic protection through a multimodal approach to risk stratification. Trial Registration: TAILOR‐PCI URL: https://clinicaltrials.gov/ct2/show/NCT01742117

  • Open Access

    2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping

    by Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees, Jasmine A. Luzum, George A. Stouffer, Jurriën M. Ten Berg, Wout W. A. van Den Broek, Naveen L. Pereira, Dirk Sibbing, Dominick J. Angiolillo

    The 2025 American College of Cardiology/American Heart Association/American College of Emergency Physicians/National Association of Emergency Medical Services Physicians/Society for Cardiovascular Angiography & Interventions acute coronary syndrome guideline focuses on strategies to reduce bleeding risk with antiplatelet therapy yet lacks any recommendation related to CYP2C19 genotyping. The impact of CYP2C19 loss‐of‐function alleles on the effectiveness of clopidogrel is well documented, and although prasugrel and ticagrelor more effectively reduce the risk for atherothrombotic events compared with clopidogrel in patients with a CYP2C19 loss‐of‐function allele, clopidogrel reduces bleeding risk without an increase in atherothrombotic events compared with prasugrel or ticagrelor in those without a loss‐of‐function allele. Accordingly, an American Heart Association Scientific Statement supports CYP2C19 genetic testing before oral P2Y 12 inhibitors are prescribed. This commentary summarizes the evidence in support of CYP2C19 ‐guided P2Y 12 inhibitor selection in the context of other 2025 acute coronary syndrome guideline recommendations and urges future guidelines to incorporate recommendations for CYP2C19 genotyping, especially for those at high bleeding risk.


  • REPLY

    by Mattia Galli, Naveen L. Pereira, Jurrien Ten Berg, Dominick J. Angiolillo

  • Open Access

    Trends and Predictors of Premature Termination of Cardiovascular Trials

    by Frederick Berro Rivera, Nathan Ross B. Bantayan, John Vincent Magalong, Chieh-Mei Tsai, Nicole Tesoro, Polyn Luz S. Pine, Neill Steven Cainglet Cachuela, Sung Whoy Cha, Christine J. Lin, Vuyisile T. Nkomo, et al.


  • Novel association of NAV3 with dilated cardiomyopathy and its role in cardiac fibrosis

    by Min Wang, Rachad Ghazal, Akshatha N. Srinivas, Thanh Thanh L. Nguyen, Vishakantha Murthy, Dennis M. McNamara, Michelle K. Skime, Anthony Batzler, Gregory D. Jenkins, Simona Barlera, et al.

    This study uncovers a previously unrecognized role for NAV3 in TGF-β1-driven cardiac fibroblast activation. We show that NAV3 facilitates profibrotic remodeling through noncanonical signaling and cell cycle arrest, independently of SMAD2/3. These findings position NAV3 as a novel regulator of fibroblast phenotype and a potential modulator of cardiac fibrosis.


  • Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome

    by Mattia Galli, Naveen L. Pereira, Ryan J. Lennon, Wout W.A. van Den Broek, Daniel M.F. Claassens, Thomas O. Bergmeijer, Yves Rosenberg, Luca Fazzini, Vera H.M. Deneer, M. Hassan Murad, et al.


  • Open Access

    Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection

    by Rachad Ghazal, Min Wang, Akshatha N. Srinivas, Jenny J. Cao, Hridyanshu Vyas, Duan Liu, Asha Nair, Byron H. Smith, Li Wang, Daniel S. Yip, et al.

    Background.: Acute cellular rejection (ACR) remains a major cause of morbidity after heart transplantation despite advances in immunosuppression. Whole genome transcriptomic profiling offers a systems-based, unbiased approach to elucidate the molecular mechanisms underlying ACR. However, noninvasive, longitudinal biomarker assessments capable of capturing the temporal dynamics of rejection biology remain scarce. Methods.: RNA sequencing of peripheral blood from heart transplant recipients before, during, and after ACR was compared with nonrejection controls. Pathway analysis was conducted using differentially expressed genes (DEGs), and a machine learning approach was applied to assess gene-based prediction of ACR. Results.: A total of 235 rejection-specific significant DEGs and 863 postrejection DEGs (false discovery rate < 0.05) were identified. During ACR, DEGs were enriched for T-cell activation/differentiation, apoptosis, and B-cell receptor signaling pathways. By combining the 2 sets of DEGs, a panel of 71 common genes was identified that reflected the significant, longitudinal transcriptomic dynamics of ACR. In an elastic net machine learning–based classifier, DYNLL1 and SERF2 were identified as ACR predictive genes, and achieved a cross-validated area under the receiver operating characteristic curve of 0.63. Conclusions.: Peripheral blood transcriptomics identify dynamic temporal responses in ACR including T- and B-cell pathways with potential ACR predictive genes that warrant further investigation.

  • Open Access

    Reply

    by Naveen L. Pereira, Matteo Castrichini, Luca Fazzini

  • Open Access

    Titin-related familial dilated cardiomyopathy: factors associated with disease onset

    by Renee Johnson, Robert A Fletcher, Stacey Peters, Monique Ohanian, Magdalena Soka, Andrei Smolnikov, Katherine E Abihider, Michael J Ackerman, Flavie Ader, Mohammed M Akhtar, et al.

    Background and Aims: Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. Methods: An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. Results: A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80–30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06–5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27–3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35–9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08–.23). Conclusions: Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.